STIM vs. PDEX, NVNO, MGRM, SEPA, HSAQ, SRTS, NSPR, BWAY, DRIO, and ICCM
Should you be buying Neuronetics stock or one of its competitors? The main competitors of Neuronetics include Pro-Dex (PDEX), enVVeno Medical (NVNO), Monogram Orthopaedics (MGRM), SEP Acquisition (SEPA), Health Sciences Acquisitions Co. 2 (HSAQ), Sensus Healthcare (SRTS), InspireMD (NSPR), BrainsWay (BWAY), DarioHealth (DRIO), and IceCure Medical (ICCM). These companies are all part of the "surgical & medical instruments" industry.
Pro-Dex (NASDAQ:PDEX) and Neuronetics (NASDAQ:STIM) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, community ranking, media sentiment, valuation, risk, analyst recommendations and institutional ownership.
In the previous week, Neuronetics had 5 more articles in the media than Pro-Dex. MarketBeat recorded 6 mentions for Neuronetics and 1 mentions for Pro-Dex. Neuronetics' average media sentiment score of 1.91 beat Pro-Dex's score of 0.07 indicating that Pro-Dex is being referred to more favorably in the media.
Pro-Dex received 20 more outperform votes than Neuronetics when rated by MarketBeat users. However, 68.48% of users gave Neuronetics an outperform vote while only 60.58% of users gave Pro-Dex an outperform vote.
Pro-Dex has higher earnings, but lower revenue than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.
Pro-Dex has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500. Comparatively, Neuronetics has a beta of 2.5, suggesting that its stock price is 150% more volatile than the S&P 500.
15.3% of Pro-Dex shares are owned by institutional investors. Comparatively, 53.6% of Neuronetics shares are owned by institutional investors. 42.6% of Pro-Dex shares are owned by insiders. Comparatively, 9.8% of Neuronetics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Pro-Dex has a net margin of 4.13% compared to Pro-Dex's net margin of -37.61%. Neuronetics' return on equity of 6.50% beat Pro-Dex's return on equity.
Neuronetics has a consensus price target of $8.00, indicating a potential upside of 206.51%. Given Pro-Dex's higher probable upside, analysts clearly believe Neuronetics is more favorable than Pro-Dex.
Summary
Pro-Dex beats Neuronetics on 10 of the 17 factors compared between the two stocks.
Get Neuronetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for STIM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding STIM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Neuronetics Competitors List
Related Companies and Tools
